Ascrinvacumab (PF-03446962) is a highly humanized IgG2 monoclonal antibody against ALK-1 with a Kd value of 7 nM for human ALK1. It has an inhibitory effect on TGF-β and can be used to study hepatocellular carcinoma (HCC).

ALK1 (human):7 nM(Kd)

Ascrinvacumab binds to human ALK1 with a Kd value of 7 nM[1].
In a 30-minute treatment, Ascrinvacumab blocks the response induced by BMP9 and FCS, alleviating BMP9-induced Smad1 phosphorylation intensity and duration[1].
At concentrations ranging from 0.01 to 10 μg/mL for 2 hours, Ascrinvacumab inhibits the binding of BMP9 to ALK1[1].
At 40 μg/mL for 2 hours, Ascrinvacumab effectively inhibits endothelial sprouting in human umbilical vein endothelial cells (HUVECs)[1].

In a mouse xenograft tumor model, the combination of Ascrinvacumab with bevacizumab (anti-VEGF) reduces human vascular density and enhances the anti-tumor efficacy[1].